Technology | September 05, 2014

Protek Duo Veno-Venous Cannula Receives FDA 510(k) Clearance

September 5, 2014 — CardiacAssist announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new Protek Duo veno?venous cannula. The Protek Duo is intended for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support (ECLS) procedures.

According to estimates from the National Heart, Lung and Blood Institute (NHLBI), approximately 190,000 Americans are affected by acute respiratory distress syndrome (ARDS) every year. Despite receiving therapy with mechanical ventilation, which is widely considered the standard of care, approximately 40 percent of patients diagnosed with ARDS will die as a result of the disease.

Veno?venous extracorporeal life support (VV ECLS) is an emerging therapy designed to provide a higher level of support by infusing oxygen directly into the blood using an oxygenator. In one large randomized, controlled clinical trial of 180 adult ARDS patients, the use of advanced VV ECLS therapy was shown to reduce the rate of death and disability by 31 percent compared to conventional management with mechanical ventilation.

The Protek Duo cannula is designed to address two major roadblocks that have prevented VV ECLS therapy from becoming a new standard of care: the difficulty of initiating and maintaining a patient on VV ECLS support, and suboptimal gas exchange rates with currently available devices. Insertion of the Protek Duo cannula can be performed through a minimally invasive percutaneous procedure, and patient management is simplified by combining with the lightweight and compact TandemHeart pump, which can be placed directly on the patient.

The TandemHeart platform is designed to simplify patient ambulation and enable freedom of movement not possible with mechanical ventilation or any alternative ECLS device. “The percutaneous internal jugular approach of this promising new technology will give us the ability to minimize the morbidity usually associated with central ECLS cannulation. By optimizing patient mobility, we also expect to reduce the long-term negative effects of severe deconditioning. The ECLS community welcomes these innovative medical devices designed to help physicians improve patient outcomes,” said Jose P. Garcia, M.D., surgical director of cardiothoracic transplantation and the Artificial Heart & Lung Program at Massachusetts General Hospital in Boston.

“TandemHeart has been focused on the treatment of heart failure since the company’s inception in 1996. The U.S. launch of Protek Duo with our TandemHeart platform is propelling our company into a new era, creating innovative products for both heart and respiratory failure. This will mark our third product launch in the past year, and we are excited and proud to be launching many more new products over the next 12 months,” said John Marous, president and CEO of CardiacAssist.

For more information: www.cardiacassist.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init